Abstract | BACKGROUND: PATIENTS AND METHODS: RESULTS: During 22 months, 46 patients were included in a single institution. The primary end point, fraction of progression-free survival (PFS) at 6 months, was 31/42 [74%; 95% confidence interval (CI) 58% to 84%]. Forty-two patients had measurable disease. Response rate was 33% and disease control rate 86%. Median PFS was 8.3 months (95% CI 6.7-8.7 months) and median overall survival was 10.0 months (95% CI 7.4-12.7 months). Toxicity was manageable including eight cases of epidermal growth factor receptor-related skin adverse events of grade 2 or more. CONCLUSIONS:
|
Authors | L H Jensen, J Lindebjerg, J Ploen, T F Hansen, A Jakobsen |
Journal | Annals of oncology : official journal of the European Society for Medical Oncology
(Ann Oncol)
Vol. 23
Issue 9
Pg. 2341-2346
(Sep 2012)
ISSN: 1569-8041 [Electronic] England |
PMID | 22367707
(Publication Type: Clinical Trial, Phase II, Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antibodies, Monoclonal
- Biomarkers, Tumor
- KRAS protein, human
- Organoplatinum Compounds
- Proto-Oncogene Proteins
- Oxaliplatin
- Deoxycytidine
- Capecitabine
- Panitumumab
- ErbB Receptors
- Proto-Oncogene Proteins p21(ras)
- ras Proteins
- Fluorouracil
- Gemcitabine
|
Topics |
- Adult
- Aged
- Aged, 80 and over
- Antibodies, Monoclonal
(administration & dosage)
- Antineoplastic Combined Chemotherapy Protocols
(adverse effects, pharmacology, therapeutic use)
- Biliary Tract Neoplasms
(drug therapy, metabolism, mortality)
- Biomarkers, Tumor
(metabolism)
- Capecitabine
- Cholangiocarcinoma
(drug therapy, metabolism, mortality)
- Deoxycytidine
(administration & dosage, analogs & derivatives)
- Disease-Free Survival
- ErbB Receptors
(antagonists & inhibitors, metabolism)
- Female
- Fluorouracil
(administration & dosage, analogs & derivatives)
- Humans
- Kaplan-Meier Estimate
- Male
- Middle Aged
- Organoplatinum Compounds
(administration & dosage)
- Oxaliplatin
- Panitumumab
- Proto-Oncogene Proteins
(genetics)
- Proto-Oncogene Proteins p21(ras)
- Statistics, Nonparametric
- Treatment Outcome
- ras Proteins
(genetics)
- Gemcitabine
|